<DOC>
	<DOCNO>NCT02562508</DOCNO>
	<brief_summary>This bridge trial recombinant HPV 16/18 bivalent vaccine manufacture Xiamen Innovax Biotech CO. , LTD.The primary objective study evaluate immunogenicity ( type specific IgG antibody ) safety test vaccine administer girl age 9-17 year non-inferior young healthy adult 18-26 year accord standard 3-dose schedule ( 0,1,6 month ) . Meanwhile , study try compare difference safety immunogenicity among different schedule ( 0-6m v 0-1-6m ) .</brief_summary>
	<brief_title>A Bridging Study Recombinant Human Papillomavirus 16/18 Bivalent Vaccine Preadolescent Girls</brief_title>
	<detailed_description>Totally 750 healthy girl 9-17 year 225 healthy young woman 18-26 year enrol . The subject 9-14 year stratify 2 subset . Subjects subset randomly assign standard 0-1-6m schedule group alternative 0-6m group . All subject 15-26 year age receive standard 0-1-6m schedule . Participants actively monitor adverse event 1 month injection . Severe adverse event trial follow . Serum sample subject would collect day 0 , 6m , 7m evaluate immunogenicity .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Females age 9 26 year receive first vaccination ( 9≤age &lt; 27 ) ; 2 . Participants age 917 year whose legal guardian provide identity certificate , representative provide authorization ; 3 . Judged healthy eligible vaccination investigator selfreported medical history physical examination ; 4 . Participants age 917 year , able sign whose legal guardian agree sign write informed consent ; participant aged 1826 year agree sign write informed consent ; 5 . Able comply request study ; 6 . Axillary temperature high 37.0°C ; 7 . Nonpregnancy verify urine pregnancy test ; Exclusion criterion : 1 . Pregnant lactate woman woman willing intend become pregnant next 7 month ; 2 . Use investigational nonregistered product ( drug vaccine ) within 30 day precede first vaccination , plan use study period ; 3 . Participants receive immunosuppressive agent immunomodulator agent long term ( 14 day ) within 6 month first vaccination , systematic corticosteroid ( however , topical corticosteroid allow , ointment , eye drop , inhalant , nasal spray ) ; 4 . Participants receive immunoglobulin and/or blood product 3 month prior first vaccination , plan receive study period ; 5 . Use inactivate vaccine 14 day precede dose study vaccine attenuate vaccine 21 day enrollment ; 6 . Participants fever ( auxiliary temperature ≥38.0 °C ) within 3 day prior vaccination , acute disease require systematic antibiotic antiviral therapy within past 5 day ; 7 . Concurrently participate another clinical trial ; 8 . Participants receive HPV vaccine ; 9 . Participants immunodeficiency disease ( HIV positive ) , primary disease vital organ , cancer ( precancerous lesion ) , chronic history immunological disease require treatment ( include systemic lupus erythematosus ) , rheumatoid arthritis , asplenia splenectomy due condition , immunological disease may impact immune response consider investigator ) , etc . ; 10 . Participants history allergy , include severe adverse reaction due past vaccination , hypersensitivity , urticaria , dyspnea , angioneurotic edema , abdominal pain ; 11 . Participants asthma , unstable past 2 year , require emergency treatment , hospitalization , oral intravenous corticosteroid ; 12 . Participants concurrent severe medical disorder , hypertension , heart disease , diabetes mellitus , hyperthyroidism , etc . ; 13 . Participants coagulation dysfunction ( coagulation factor deficiency , bloodclotting disorder , platelet disorder ) coagulation disorder , diagnose physician ; 14 . Participants epilepsy , exclude febrile epilepsy patient 2 year old , alcoholic epilepsy 3 year prior alcohol abstinence , pure epilepsy require treatment within past 3 year ; 15 . Participants compliant study 's requirement due psychological condition , prior exist mental disease bipolar psychosis well control within past 2 year require take drug , suicidal tendency within past 5 year ; 16 . According investigator 's judgment , might medical , psychological , social occupational factor might impact individual obey protocol sign informed consent ;</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Human Papilloma Virus 16</keyword>
	<keyword>Human Papilloma Virus 18</keyword>
	<keyword>vaccine</keyword>
	<keyword>adolescent girl</keyword>
	<keyword>bridge trial</keyword>
	<keyword>non-inferiority</keyword>
</DOC>